Introduction
Retinoids are natural and synthetic analogs of vitamin A (retinol) that regulate many cellular processes, including growth, differentiation and apoptosis (Nagy et al., 1998) . N-(4-hydroxyphenyl)retinamide or fenretinide (4-HPR), a synthetic derivative of all-trans-retinoic acid (RA), has emerged as one of the most promising retinoids in clinic. 4-HPR, unlike other retinoids, is well tolerated in humans (Veronesi et al., 1999) . In addition, 4-HPR may be effective in reducing premalignant lesions (Chiesa et al., 2005) , and it has been shown to possibly reduce the occurrence of ovarian cancer (De Palo et al., 2002) and to induce, in premenopausal women, a significant risk reduction of second breast cancer that persists for at least 15 years (Veronesi et al., 2006) .
The mechanisms of action of 4-HPR are still under investigation. Whereas the classical retinoids often induce differentiation, 4-HPR mainly promotes growth inhibition and apoptosis. Some studies have suggested that 4-HPR acts through both retinoid receptor-dependent and -independent mechanisms (Clifford et al., 1999) and that the induction of apoptosis is mediated, at least in part, by an increase of the intracellular levels of ceramide (Wang et al., 2001; Prinetti et al., 2003) , generation of oxygen species (Lovat et al., 2004) and alteration of mitochondrial membrane potential (Hail and Lotan, 2001 ). Several studies have been focused on the identification of genes implicated in 4-HPR-induced apoptosis. Activation of p38 (MAPK) (Myatt et al., 2005) , downregulation of nuclear factor-kB-regulated proteins involved in antiapoptosis, proliferation and angiogenesis (Shishodia et al., 2005) , and induction of c-Fos , GADD153 (Lovat et al., 2004) , Bak (Lovat et al., 2004) and BBC3 (Wei et al., 2005) have been shown to mediate 4-HPR apoptosis in cancer cells.
This study was designed to explore the mechanisms underling 4-HPR action and to identify genes that contribute to its activity in ovarian cancer cells. Using cDNA microarrays, we monitored gene expression changes after exposure to 4-HPR in A2780, a human ovarian carcinoma cell line very sensitive to the retinoid . Among the several 4-HPRmodulated genes, the proapoptotic gene PLAcental Bone morphogenetic protein (PLAB) was the most highly induced. By PLAB overexpression we provide evidence of a role of this protein in basal apoptosis and, by suppressing its expression by small interfering (si)RNA, we demonstrate a functional involvement of PLAB in 4-HPR-induced apoptosis. We also show that, in a panel of six ovarian cancer cell lines, PLAB upregulation and 4-HPR sensitivity are closely associated and that 4-HPR does not regulate PLAB expression through p53 and EGR-1 transcription factors but by PLAB mRNA stabilization. Finally, we demonstrate that PLAB upmodulation also occurs in vivo, in ascitic cells of patients with ovarian cancer treated with the retinoid before tumor removal.
Results

Microarray data of 4-HPR-modulated genes in A2780 cells
We examined by cDNA microarray analysis the gene expression profiles of A2780 cells untreated and exposed to 5 mM 4-HPR for 24 h, a dose that causes apoptosis and which can be achieved in human plasma with minimal side effects (Garaventa et al., 2003) .
Out of a total of 8473 genes examined, 41 and 55 transcripts were found to be up-and downregulated, respectively (Tables 1 and 2 ). The genes were classified into functional categories to identify the presence of significantly enriched groups using the Expression Analysis Systematic Explorer (EASE) tool (Hosack et al., 2003; see Supplementary Information) . Transcripts increased by 4-HPR were associated with proteolysis and peptidolysis (EASE score 0.0392) and protein catabolism (EASE score 0.0473). A significant number of transcripts downmodulated by 4-HPR fell within the categories of oxidative phosphorylation (EASE score 0.003), energy pathways (EASE score of 0.0194), amino acid and derivative metabolism (EASE score 0.0353) and energy derivation by oxidation of organic compounds (EASE score 0.0466). Some of the identified transcripts modulated by 4-HPR, 7/41 Tables 1 and 2 .
The microarray data were validated by evaluating with reverse transcriptase-polymerase chain reaction (RT-PCR) or Western blot analysis the expression levels of seven representative genes from the up-and downregulated gene lists (Figure 1 ): PLAB, cysteine-rich 61 (CYR61), heat shock 70 kDa (HSP70), interferoninduced transmembrane protein 2 and 3 (IFITM 2 and 3), collagen type III (COL3A1) and dihydrofolate PLAB in 4-HPR-induced apoptosis V Appierto et al reductase. PLAB mRNA levels were also validated by real time-quantitative PCR (for Materials and methods see Supplementary Information) and the results of the analysis confirmed the high PLAB upmodulation (27.5-fold) (data not shown).
4-HPR effect on PLAB expression in A2780 and A2780/HPR cells
Among the genes identified by the microarray analysis as differentially expressed, PLAB was the most 4-HPR upregulated gene. Based on the fact that PLAB expression is linked to cell growth arrest and apoptosis (Baek and Eling, 2006) and to its dramatic induction by 4-HPR, we focused on PLAB gene. Induction of PLAB in A2780 cells by 4-HPR also occurred at the protein level ( Figure 2a ). Specifically, treatment with 5 and 10 mM 4-HPR caused a strong dose-dependent protein increase. PLAB expression was undetectable in A2780 untreated cells unless the film was exposed for a long time. Time-course analysis showed no upregulation of PLAB protein at 6 h whereas at 24 h it was already upmodulated and its expression increased up to 48 h ( Figure 2b ). To understand whether the observed PLAB upregulation by 4-HPR was related to 4-HPR apoptotic-inducing effects, the analysis of PLAB expression was extended to A2780/HPR cells, which are 4-HPRresistant cells and which do not undergo apoptosis even after 10 mM 4-HPR (Appierto et al., 2001 . Contrary to A2780 cells, A2780/HPR cells showed, following 4-HPR exposure, only a slight upregulation of PLAB expression whose final levels were much lower than those observed in 4-HPR sensitive cells ( Figure 2c ). Such findings suggested an association between 4-HPRinduced PLAB upregulation and the ability of the retinoid to induce apoptosis.
4-HPR sensitivity and PLAB induction in a panel of human ovarian cancer cell lines. Influence of p53 on PLAB upregulation
To assess whether the upregulation of PLAB and its association with 4-HPR sensitivity observed in A2780 cells were general features of ovarian cancer cells, the analysis of PLAB expression was extended to a panel of human ovarian carcinoma cell lines with different sensitivity to 4-HPR. The role of p53 status on PLAB induction by 4-HPR was also assessed because the relationship between p53 expression and PLAB induction is controversial (Albertoni et al., 2002; Baek et al., 2002; Newman et al., 2003) . The effect of the retinoid on the proliferation of the different cancer cell lines was evaluated and the respective inhibiting concentrations 50% (IC 50 ) were calculated and reported in Figure 3a together with the p53 status (Perego et al., 1996 for OVCA432 and OVCAR-3). Sensitivity to 4-HPR was different for the six cell lines: 50% growth inhibition was achieved with 1.5 mM 4-HPR in A2780, the most sensitive cell line, whereas the IC 50 s of 4-HPR were 3 and 5 mM for IGROV-1/Pt and IGROV-1, respectively, 8 mM for both OVCA432 and SKOV-3, and 10 mM for OVCAR-3, the most 4-HPR-resistant. The analysis of PLAB expression in these cell lines showed that treatment with 5 and 10 mM 4-HPR for 24 h increased, in a dose-dependent manner, the levels of PLAB in A2780, IGROV-1/Pt and IGROV-1. In OVCA432 and SKOV-3, a very slight upmodulation of PLAB occurred only after 10 mM 4-HPR and no upregulation was observed in OVCAR-3 cells (Figure 3b ). The data suggest a correlation between the ability of 4-HPR to upregulate the protein and the cellular response to the retinoid. Moreover, the results indicate that p53 does PLAB in 4-HPR-induced apoptosis V Appierto et al not contribute to PLAB induction by 4-HPR, because PLAB upmodulation was similar in p53 wild-type cells and in their p53 mutant counterpart (IGROV-1 and IGROV-1/Pt, respectively) and it also occurred in p53-null-type cells (SKOV-3).
Effect of different retinoids on PLAB expression in A2780 cells
The analysis of the association between PLAB expression and tumor growth inhibitory effects was extended to other retinoids. We have previously demonstrated that 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) and 4-oxo-N-(4-hydroxyphenyl) retinamide (4-oxo-4-HPR), a 4-HPR metabolite, have growth inhibitory effects in A2780 cells, whereas N-(4-methoxyphenyl)retinamide (4-MPR), 13-cis-retinoic acid (13-cis-RA) and RA do not affect their growth (Appierto et al., 2001; Villani et al., 2004) . The IC 50 of the retinoids in A2780 cells are reported in Figure 4a . PLAB expression in A2780 cells (Figure 4b ) was strongly upmodulated by CD437 and 4-oxo-4-HPR, the two active retinoids, whereas it was not affected by 4-MPR, 13-cis-RA and RA. The results indicate that not only 4-HPR but also other retinoids induce PLAB expression and that this molecular event is associated with the ability of the retinoid to inhibit cell growth. Dose-dependent analysis of PLAB upmodulation by 4-HPR and 4-oxo-4-HPR (1, 3, 5 and 10 mM) was also performed. 4-oxo-4-HPR, despite its greater potency, did not increase PLAB expression at lower concentrations than 4-HPR (data not shown).
PLAB induction by 4-HPR in human breast cancer cells
The analysis of PLAB expression was extended to breast cancer cells examining its induction by 4-HPR in MCF-7 and T-47D, two breast cancer cell lines sensitive to 4-HPR and with different p53 status (Lu et al., 2001 ; Figure 5 ). The IC 50 s were 2.4 and 4 mM in MCF-7 and Regulation of PLAB at transcriptional and post-transcriptional level Transcriptional and post-transcriptional regulation mechanisms have been described in the control of PLAB expression (Baek and Eling, 2006 (Figure 6a and b) than in 4-HPR-treated cells (half-life >8 h), suggesting that the increase in stability of PLAB mRNA is a mechanism involved in the induction of PLAB protein by 4-HPR. Finally, to examine whether 4-HPR-induced PLAB expression requires de novo synthesis, A2780 cells were pretreated with cycloheximide (CHX) followed by treatment with 4-HPR. 4-HPR-induced PLAB mRNA was reduced by the presence of CHX (Figure 6c ) indicating that the effect of 4-HPR on PLAB expression requires de novo protein synthesis.
Effect of PLAB overexpression in apoptosis and of PLAB silencing in 4-HPR-mediated apoptosis
To investigate the association between PLAB induction and apoptosis, we determined whether direct overexpression of PLAB in the absence of external stimuli could cause apoptosis. To this aim, A2780 cells were transiently transfected with an expression vector containing the full-length PLAB-coding region To study the potential role of PLAB in 4-HPRmediated apoptosis, A2780 cells were transiently transfected with a plasmid expressing a PLAB siRNA or a scrambled nonsilencing siRNA and were then tested for their sensitivity to 4-HPR-apoptotic inducing effects. PLAB induction was repressed in cells transfected with the PLAB siRNA plasmid compared with cells transfected with the scrambled plasmid (Figure 7c ). The apoptosis induced by 4-HPR in cells transfected with PLAB siRNA was markedly reduced (by 53 and 76% after 5 and 10 mM 4-HPR, respectively) (Figure 7d ). Consistent results were obtained when the effect of PLAB silencing on 4-HPR-induced apoptosis was analyzed by TUNEL assay on A2780 cells stably transfected with the PLAB siRNA or with the scrambled plasmids. In a representative experiment, the percentage of apoptotic cells 24 h after treatment was in scrambled transfected cells: controls ¼ 2.5%, 5 mM 4-HPR ¼ 18% and 10 mM 4-HPR ¼ 43%, and in PLAB silenced cells: controls ¼ 3%, 5 mM 4-HPR ¼ 3.1% and 10 mM 4-HPR ¼ 13.7%. Such results indicate that elevation of PLAB expression is functionally involved in 4-HPRinduced apoptosis.
PLAB induction by 4-HPR in tumor cells of treated patients
To investigate whether the observed PLAB upmodulation by 4-HPR also occurs in vivo, we analyzed PLAB expression in ascitic cancer cells collected before and after treatment from patients with ovarian cancer treated with escalating doses of 4-HPR for 1-4 weeks before surgery. Among the six investigated patients, only one patient expressed PLAB at baseline (Figure 8) . No variation in PLAB expression was observed in the two control patients, whereas PLAB upmodulation occurred in 2/4 patients treated with 4-HPR (400 and 800 mg/day, respectively). The results indicate that 4-HPR can cause an increase of PLAB expression in tumor cells of treated patients.
Discussion
4-HPR is one of the most promising retinoid tested in the clinic and preclinical and clinical data support its investigation for ovarian cancer prevention and treatment (De Palo et al., 2002; Formelli and Cleris, 1993) . To identify genes that contribute to the apoptotic action of 4-HPR in ovarian cancer cells, we examined by cDNA microarray analysis gene expression changes after 4-HPR treatment in A2780, a human ovarian carcinoma cell line very sensitive to the retinoid . Several genes were identified as upand downmodulated by 4-HPR. Among the 4-HPRdownmodulated genes, significantly represented were transcripts encoding for enzymes involved in aminoacid metabolism, oxidation of organic compounds and oxidative phosphorylation, the most significantly overrepresented category.
A significant number of transcripts upmodulated by 4-HPR were related with proteolysis and protein catabolism, probably resulting in general cell degradation, PLAB in 4-HPR-induced apoptosis V Appierto et al or in selective destruction of proteins involved in the control and execution of apoptosis. Some of the identified transcripts modulated by 4-HPR have been already described as RA-regulated genes (Dziadek and Timpl, 1985; Cui et al., 2001; Balmer and Blomhoff, 2002; Tsai et al., 2002; Ma et al., 2003; Zhao et al., 2004) . One of them, the epidermal growth factor receptor, was downmodulated by 4-HPR also in human breast cancer cells (Pellegrini et al., 1995) . Among the genes that we have identified, PLAB, also known as nonsteroidal antiinflamatory drug-activated gene-1, macrophage inhibitory cytokine-1, placental TGF-b, prostate-derived factor, or growth differentiation factor-15, was the most upregulated by 4-HPR. PLAB encodes a protein sharing homologies with members of the transforming growth factor-b superfamily. The biological activity of PLAB is not well characterized; however, its expression has been linked to anti-inflammatory activity and to cancer cell growth arrest and apoptosis (Baek and Eling, 2006) . Many antitumorigenic agents such as resveratrol, diallyl disulfide and genistein (Baek and Eling, 2006) increased PLAB levels in tumor cells.
Based on its dramatic induction by 4-HPR in A2780 cells and on our interest in genes that mediate 4-HPR apoptotic effects, we focused the study on PLAB. 4-HPR greatly enhanced the expression of PLAB protein in a time-and dose-dependent manner in A2780 cells and a clear association between PLAB upmodulation and 4-HPR sensitivity was observed. In A2780/HPR cells, a 4-HPR-resistant variant derived from A2780 cells, the retinoid caused only a slight upregulation of the protein that was dramatically lower than that observed in sensitive cells. The association between 4-HPR sensitivity and PLAB upmodulation was confirmed in a panel of human ovarian and breast carcinoma cell lines with different 4-HPR sensitivities. In cells requiring high 4-HPR concentrations for growth inhibition (IC 50 >8 mM), no upmodulation was found after 5 mM, and a very slight or no upregulation occurred after 10 mM. In cells with IC 50 s ranging from 1.5 to 5 mM, PLAB expression increased already after 5 mM 4-HPR. The increase in PLAB expression in IGROV-1 and IGROV-1/Pt treated with 5 mM 4-HPR, a concentration almost equivalent to the IC 50 s, was very small. It has to be pointed out that whereas the IC 50 s were evaluated 72 h after drug treatment, PLAB modulation was assessed at 24 h, and further increase in PLAB induction could have occurred at longer times.
Evidence of a role for PLAB in the onset of apoptosis in ovarian cancer cells was obtained using PLAB transfected A2780 cells that, in the absence of external stimuli, exhibited increased apoptosis rate. The causal relationship between upregulation of PLAB expression and 4-HPR-induced apoptosis was also established. In A2780 cells PLAB silencing caused a marked, even if not complete, reduction in 4-HPR-induced apoptosis. These findings indicate that PLAB is, at least in part, responsible for 4-HPR-induced apoptosis.
PLAB has been described as an RA-target gene, directly implicated in RA signaling (Ma et al., 2003) . When different retinoids were tested in A2780 cells, the upregulation of PLAB was selectively associated with the ability of the retinoids to inhibit cell growth. PLAB expression was upregulated by 4-HPR, CD437 and 4-oxo-4-HPR, three retinoids that displayed growth inhibitory effects in A2780 cells, but not by the ineffective 4-MPR, 13-cis-RA or RA. Thus, supporting the hypothesis that upregulation of PLAB is tightly associated with induced cell death, not only for 4-HPR, but also for other retinoids. It has been recently reported that 4-HPR, at variance with CD437 and other potent retinoid-related molecules, did not induce PLAB expression in lung carcinoma cells (Kadara et al., 2006) . However, it has to be pointed out that 4-HPR was tested at 0.5 mM, a dose possibly not effective in inducing cell death.
PLAB expression has been reported to be regulated by different transcription factors including p53 and EGR-1 that have been identified as PLAB inducers. Our results indicate that PLAB upregulation by 4-HPR does not require p53 because it was observed in cells with different p53 status, including p53-null cells. Our data also indicate that modulation of PLAB expression by 4-HPR does not involve EGR-1 because its expression was unaffected by 4-HPR treatment. We found instead that the stability of PLAB mRNA plays a role in 4-HPR-induced PLAB expression because the retinoid increased the half-life of PLAB transcript. Posttranscriptional regulation of PLAB expression through PLAB mRNA stabilization has been also described for the retinoid CD437 (Newman et al., 2003) . The findings that CHX reduces PLAB induction by 4-HPR indicates that PLAB mRNA stabilization by 4-HPR is due, at least in part, to de novo protein synthesis.
PLAB modulation by 4-HPR also occurred in vivo, in ascitic cancer cells collected from patients with ovarian PLAB in 4-HPR-induced apoptosis V Appierto et al cancer treated with the retinoid. Among the investigated patients, two controls and four treated, PLAB was upmodulated in 2/4 treated patients. The phase I-II trial was run in patients with ascitic ovarian cancer to evaluate toxicity, drug concentrations and markers of activity of escalating doses of 4-HPR (Colombo et al., 2006) . 4-HPR doses up to 800 mg/day did not show any noticeable biological activity measured as changes in Ki-67 expression, cytomorphometric parameters and serum CA125. A possible explanation for the lack of evidence of drug activity is that the biomarkers measured in the study might not be the most predictive and apoptosis detection might better correlate with the drug anticancer effect. Therefore, the role of the observed PLAB upmodulation in 4-HPR activity cannot be ruled out. Interestingly, PLAB induction in humans has been observed following neoadiuvant therapy in breast cancer biopsies and also in that case, the correlation with response to therapy was not known (Modlich et al., 2004) .
In summary, we report that in ovarian carcinoma cells sensitive to 4-HPR, 4-HPR treatment resulted in induction of PLAB and that PLAB silencing caused a severe reduction in 4-HPR-induced apoptosis. PLAB induction was not due to transcriptional regulation by p53 and EGR-1, but it was mediated by PLAB mRNA stabilization. We also demonstrate that PLAB upmodulation also occurs in vivo and future studies on the association between PLAB modulation in tumors and response to 4-HPR might reveal PLAB levels as a biomarker of 4-HPR activity.
Materials and methods
Cell lines and reagents
Seven human ovarian and two breast carcinoma cell lines whose origin and culture conditions have been previously described (Villani et al., 2006) were investigated. The ovarian carcinoma cell lines were: A2780, A2780/HPR, IGROV-1, IGROV-1/Pt (generated by Dr Perego) (Perego et al., 1996) , OVCA-432, OVCAR-3 and SKOV-3. The breast tumor cell lines were: T-47D and MCF-7. 4-HPR and 4-MPR were provided by Dr Crowell (National Cancer Institute); 4-oxo-4-HPR, a 4-HPR polar metabolite , was provided by Dr Curley (Columbus, OH, USA); CD437 was obtained from CIRD/Galderma (Sophia Antipolis, France); RA and 13-cis RA were purchased from Sigma, (St Louis, MO, USA). 4-HPR, 4-MPR, RA, 13-cis-RA and CD437 were dissolved at 10 mM in dimethyl sulfoxide (DMSO), 4-oxo-4-HPR was dissolved at 10 mM in ethanol before further dilution in culture medium and stored at À801C in the dark. Actinomycin D (Sigma) was dissolved in DMSO, and CHX (Sigma) in ethanol before further dilution in culture medium and stored at À201C.
Microarray experiments A2780 cells untreated and exposed to 5 mM 4-HPR for 24 h were subjected to cDNA microarray analysis. Total RNA from cells was reverse-transcribed and fluorescently labeled, as previously described (De Cecco et al., 2004) . Genes whose expression increased or decreased >2-fold (measured as a log ratio of treated versus untreated cells) in both the replicated experiments were considered for a more detailed analysis (for technical details see Supplementary Information).
RT-PCR analysis
Semiquantitative RT-PCR analysis was performed as previously described . Target and control (b-actin) gene sequences were coamplified in the same reaction (except for CYR61) using the gene-specific oligonucleotide primers and conditions described in the Supplementary Information.
Immunoblot analysis
Proteins were extracted and processed for Western immunoblotting as described previously . The antibodies used for immunoblotting included: PLAB (Santa Cruz Biotechnology, Santa Cruz, CA, USA), HSP70 (StressGenBiotechnologies Corp., Victoria, Canada), EGR-1 (Santa Cruz Biotechnology) and Actin (Sigma).
Growth inhibition assay
Cells were seeded at a density of 7000 cells per well in 96 cluster tissue culture plates, treated the next day with different concentrations of 4-HPR or the other tested retinoids, and incubated for the indicated times. Control cultures received the same amount of DMSO or ethanol as the treated cultures. Cell number was estimated by using the sulforhodamine B assay (Skehan et al., 1990) . Three analyses were performed and four replicate wells were used for each analysis. IC 50 values (concentrations required for 50% growth inhibition) were calculated by interpolation of the sigmoidal dose-response curves.
Apoptosis assay
Fragmentation of DNA was determined by TUNEL analysis (Roche, Penzberg, Germany) according to the manufacturer's instruction, or by photometric enzyme immunoassay using Cell Death Detection ELISAplus kit (Roche) as previously described (Villani et al., 2006) .
Construction of expression vectors
The human PLAB full-length cDNA was cloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). For this purpose, PLAB cDNA was amplified from LNCaP human prostate cancer cells using the oligonucleotides PLAB-ATG (5 0 -GGAATCTGCACAGCCATGCCCGGG-3 0 ) and PLAB-960-Stop (5 0 -GCCTCGAGGCAGGTGCACAGT GGAAGGACCA-3 0 ), inserted into the plasmid pCR2.1-TOPO (Invitrogen), then subcloned into EcoRI/XhoI sites of pcDNA3.1.
To generate a plasmid containing siRNA, oligonucleotides containing an inverted repeat were cloned into pBS/U6 plasmid (a gift from Dr Yang Shi, Harvard Medical School, Boston, MA, USA) digested with ApaI and EcoRI. The selection of the coding sequence was empirically determined and analyzed by basic local alignment search tool (BLAST) analysis to avoid significant homology with any other gene in the database. The oligonucleotides used for generating PLAB siRNA were: 5 0 -GGGACCCTCAGAGTTGCACTCAAGCT TGAGTGCAACTCTGAGGGTCCCTTTTTG-3 0 and 5 0 -AA TTCAAAAAGGGACCCTCAGAGTTGCACTCAAGCTTG AGTGCAACTCTGAGGGTCCC-3 0 ; the oligonucleotides used for generating the control siRNA containing a scrambled sequence were: 5 0 -GGGTTCCTACAGCACGCTCAAAGCT TTGAGCGTGCTGTAGGAACCCCTTTTTG-3 0 and 5 0 -AA TTCAAAAAGGGGTTCCTACAGCACGCTCAAAGCTTT GAGCGTGCTTGTAGGAACCC-3 0 .
Transient and stable transfections Cells (5 Â 10 5 ) were seeded in 60 mm dishes; 24 h later, a mixture of Lipofectatmine 2000 reagent (Invitrogen) and 8 mg of expression plasmid was added and then incubated for 6 h. Cells were then cultured in medium supplemented with 10% serum for an additional 48 h before further analysis. In stable transfection, a medium containing G418 (Gibco Brl, Paisley, UK) at a concentration of 400 mg/ml was used for the selection of transfectants.
Subjects and collection of ascitic ovarian cancer cells
Patients with newly diagnosed ascitic ovarian cancer were recruited in a phase I/II study (Colombo et al., 2006) . Twentytwo patients were treated with escalating doses of 4-HPR at 0, 400, 600 and 800 mg/day for 1-4 weeks before surgery. Ascites was collected in bottles (500 cm 3 ) with heparin (1 cm 3 ), kept at room temperature and tumor cells, obtained from ascites by centrifugation, were stored at À201C before protein extractions. Ascitic cell samples for evaluation of PLAB levels expression before and after treatment were available for only six patients.
